[go: up one dir, main page]

WO1997046585A3 - Fragments de leptine (proteine ob) - Google Patents

Fragments de leptine (proteine ob) Download PDF

Info

Publication number
WO1997046585A3
WO1997046585A3 PCT/EP1997/002968 EP9702968W WO9746585A3 WO 1997046585 A3 WO1997046585 A3 WO 1997046585A3 EP 9702968 W EP9702968 W EP 9702968W WO 9746585 A3 WO9746585 A3 WO 9746585A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
compound
fragments
protein
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1997/002968
Other languages
English (en)
Other versions
WO1997046585A2 (fr
Inventor
Kamal A Al-Barazanji
Jonathan Robert Sanders Arch
Patrick Camilleri
William Arthur Neville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9611775.9A external-priority patent/GB9611775D0/en
Priority claimed from GBGB9618540.0A external-priority patent/GB9618540D0/en
Priority claimed from GBGB9703493.8A external-priority patent/GB9703493D0/en
Priority to HU0001774A priority Critical patent/HUP0001774A3/hu
Priority to AU33372/97A priority patent/AU3337297A/en
Priority to JP10500240A priority patent/JP2000512137A/ja
Priority to BR9709529A priority patent/BR9709529A/pt
Priority to NZ332879A priority patent/NZ332879A/xx
Priority to IL12715397A priority patent/IL127153A0/xx
Priority to CA002257240A priority patent/CA2257240A1/fr
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to EP97929156A priority patent/EP0912609A2/fr
Publication of WO1997046585A2 publication Critical patent/WO1997046585A2/fr
Publication of WO1997046585A3 publication Critical patent/WO1997046585A3/fr
Priority to NO985683A priority patent/NO985683D0/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une leptine, un peptide ob, ou un dérivé fonctionnel, un analogue ou un variant de ceux-ci, modulant le poids corporel essentiellement au moyen d'une modulation de l'utilisation de l'énergie. Elle concerne également une composition pharmaceutique contenant un tel composé, un procédé de préparation de celui-ci, ainsi que l'utilisation de ce composé en médecine.
PCT/EP1997/002968 1996-06-06 1997-06-04 Fragments de leptine (proteine ob) Ceased WO1997046585A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CA002257240A CA2257240A1 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)
AU33372/97A AU3337297A (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)
EP97929156A EP0912609A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)
HU0001774A HUP0001774A3 (en) 1997-02-20 1997-06-04 Fragments of leptin (ob protein)
JP10500240A JP2000512137A (ja) 1996-06-06 1997-06-04 レプチン（ｏｂタンパク質）のフラグメント
BR9709529A BR9709529A (pt) 1996-06-06 1997-06-04 Fragmentos de leptina (proteína ob)
NZ332879A NZ332879A (en) 1996-06-06 1997-06-04 Use of fragments of leptin (ob protein) in medicaments for treating obesity or diabetes
IL12715397A IL127153A0 (en) 1996-06-06 1997-06-04 Fragments of leptin (ob protein)
NO985683A NO985683D0 (no) 1996-06-06 1998-12-04 Fragmenter av leptin (ob protein)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9611775.9 1996-06-06
GBGB9611775.9A GB9611775D0 (en) 1996-06-06 1996-06-06 Novel compounds
GB9618540.0 1996-09-05
GBGB9618540.0A GB9618540D0 (en) 1996-09-05 1996-09-05 Novel compounds
GBGB9703493.8A GB9703493D0 (en) 1997-02-20 1997-02-20 Novel compounds
GB9703493.8 1997-02-20

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09194866 A-371-Of-International 1998-12-04
US09/844,774 Continuation US20020037553A1 (en) 1996-06-06 2001-04-27 Fragments of leptin (ob protein)

Publications (2)

Publication Number Publication Date
WO1997046585A2 WO1997046585A2 (fr) 1997-12-11
WO1997046585A3 true WO1997046585A3 (fr) 1998-04-23

Family

ID=27268305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/002968 Ceased WO1997046585A2 (fr) 1996-06-06 1997-06-04 Fragments de leptine (proteine ob)

Country Status (15)

Country Link
EP (1) EP0912609A2 (fr)
JP (1) JP2000512137A (fr)
KR (1) KR20000016402A (fr)
CN (1) CN1221426A (fr)
AR (1) AR008765A1 (fr)
AU (1) AU3337297A (fr)
BR (1) BR9709529A (fr)
CA (1) CA2257240A1 (fr)
CZ (1) CZ397898A3 (fr)
IL (1) IL127153A0 (fr)
NO (1) NO985683D0 (fr)
NZ (1) NZ332879A (fr)
PL (1) PL330361A1 (fr)
TR (1) TR199802534T2 (fr)
WO (1) WO1997046585A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521496A (ja) 1998-07-28 2002-07-16 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー レプチン介在性遺伝子誘導
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2388417A1 (fr) 1999-09-22 2001-03-29 Genset Procedes de criblage de composes qui modulent l'interaction de la lsr-leptine et utilisations de ces composes dans la prevention et le traitement des maladies liees a l'obesite
AU2001281784B2 (en) 2000-05-22 2005-09-15 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Receptor-based interaction trap
SI2219031T1 (sl) 2001-10-22 2013-11-29 Amgen, Inc. Uporaba leptina za zdravljenje lipoatrofije pri ljudeh in metoda za ugotavljanje dovzetnosti za navedeno zdravljenje
AU2004269927B2 (en) 2003-09-08 2009-09-17 Merck Serono Sa Treatment of fibrotic disease
CA2555877C (fr) 2004-02-11 2015-11-24 Amylin Pharmaceuticals, Inc. Polypeptides hybrides presentant des proprietes pouvant etre choisies
US7575878B2 (en) 2004-11-18 2009-08-18 Vib Vzw Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies
EA011653B1 (ru) 2005-02-11 2009-04-28 Амилин Фармасьютикалз, Инк. Аналоги и гибридные полипептиды gip с избираемыми свойствами
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
EP2330125A3 (fr) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Polypeptides hybrides ayant des propriétés sélectionnables
ES2319048B1 (es) * 2007-06-20 2010-02-10 Universitat De Les Illes Balears Uso de leptina en el tratamiento de alteraciones en los habitos alimentarios.
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
GB2451858A (en) * 2007-08-15 2009-02-18 Sergiy Konovchuk Methods of reducing body fat and treating obesity
WO2009071668A2 (fr) 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Nouveaux composés ii
CN102026975A (zh) 2007-12-05 2011-04-20 阿斯利康(瑞典)有限公司 作为抗肥胖药的哌嗪衍生物
EP2313096A1 (fr) * 2008-06-04 2011-04-27 AstraZeneca AB (Publ) Nouveaux composés v
RU2010148900A (ru) * 2008-06-04 2012-07-20 Астразенека Аб (Se) Новые производные в качестве миметиков модуляторов лептинового рецептора
EP2416797A4 (fr) 2009-04-10 2013-04-24 Amylin Pharmaceuticals Llc Composés agonistes de l'amyline pour mammifères ayant une carence en strogènes
US9475839B2 (en) * 2010-05-11 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
EP3241558B1 (fr) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Leptines hautement solubles
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
CN110183530A (zh) 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996023519A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines agissant contre l'obesite
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996005309A2 (fr) * 1994-08-17 1996-02-22 The Rockefeller University Modulateurs de masse corporelle, proteines et acides nucleiques correspondants, et utilisations a des fins therapeutiques et diagnostiques
WO1996023519A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines agissant contre l'obesite
WO1996023514A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Proteines anti-obesite
WO1996023815A1 (fr) * 1995-01-31 1996-08-08 Eli Lilly And Company Anticorps contre les produits du gene ob
WO1996031526A1 (fr) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Agents antiobesite
WO1996034885A2 (fr) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Fragments peptidiques biologiquement actifs de proteines ob

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE TOXLIT AN 1970:3841 *
K.C. SAXENA ET AL.: "Hydrolysis of Peptides containing D-amino acids by Rabbit Tissues", INDIAN JOURNAL OF BIOCHEMISTRY, vol. 6, no. 4, 1969, pages 226 - 227 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544492B1 (en) 1994-08-17 2009-06-09 The Rockefeller University OB polypeptides, modified forms and derivatives

Also Published As

Publication number Publication date
BR9709529A (pt) 1999-08-10
CN1221426A (zh) 1999-06-30
CA2257240A1 (fr) 1997-12-11
PL330361A1 (en) 1999-05-10
JP2000512137A (ja) 2000-09-19
TR199802534T2 (xx) 1999-03-22
AR008765A1 (es) 2000-02-23
NO985683L (no) 1998-12-04
NZ332879A (en) 2000-09-29
CZ397898A3 (cs) 1999-04-14
NO985683D0 (no) 1998-12-04
WO1997046585A2 (fr) 1997-12-11
AU3337297A (en) 1998-01-05
KR20000016402A (ko) 2000-03-25
EP0912609A2 (fr) 1999-05-06
IL127153A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
WO1997046585A3 (fr) Fragments de leptine (proteine ob)
AU4867697A (en) Oxadiazoles, processes for preparing them and their use as pharmaceutical compositions
HK1001495B (en) Obesity (ob) peptides capable of modulating body weight of animals, allelic variants, analogs and fragments thereof, derivatives, nucleic acid sequences, vectors, hosts and the like related thereto, and pharmaceutical compositions and related uses
WO1998007745A3 (fr) Compositions et methodes pour traitement des infections, utilisant des analogues d'indolicidine
HUP9602507A3 (en) Cyclic peptides, adhesion inhibitor pharmaceutical compositions comprising the compounds, process for the preparation of the compounds and the pharmaceutical compositions and the use of the compounds
EP1077217A3 (fr) Peptides neuroactives et leur utilisation
AU4397297A (en) Antibody against human parathormone related peptides
AP9801392A0 (en) Concentrated antibody preparation.
AU1198699A (en) Novel heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
AU4552097A (en) 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments
AU5671594A (en) Human tissue factor related dna segments, polypeptides and antibodies
AU1607497A (en) Novel aromatic piperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions, and use thereof as drugs
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
AU2974189A (en) Pharmaceutical compositions containing lactams, new substituted lactams and processes for the preparation thereof
AU4574296A (en) Aromatic heterocyclic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
EP0783521B8 (fr) Composes polypeptides contenant d-2-alkyltryptophanne pouvant promouvoir la liberation de l'hormone de croissance
AU7201298A (en) Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
AU4515497A (en) 3-amidochromanylsulfony(thio)ureas, processes for their preparation, their use, and pharmaceutical preparations comprising them
AU6858594A (en) Human influenza virus peptides binding hla-t molecule
EP0770875A3 (fr) Marqueur et réactif pour diabète sucré et complication du diabète sucré
IL110954A0 (en) Pharmaceutical compositions comprising a retinoblastoma polypeptide or protein, and methods for the preparation and use thereof
EP1174439A3 (fr) Compositions et méthodes pour traitement des infections, utilisant des analogues d'indolicidine
AU1606997A (en) Novel naphthylpiperazines derived from substituted cycloazanes, method for preparing same, pharmaceutical compositions and use thereof as drugs
ZA9710254B (en) LH-RH peptide analogues, their uses and pharmaceutical composition containing them.
AU4865796A (en) Ophthalmic compositions including peptides and peptide derivatives and methods for using same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97195311.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 332879

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1998-3978

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2257240

Country of ref document: CA

Ref document number: 2257240

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998/02534

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/010406

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997929156

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-3978

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1997929156

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997929156

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV1998-3978

Country of ref document: CZ